share_log

Biodexa Pharmaceuticals | UPLOAD: Others

SEC announcement ·  Mar 21 10:15
Summary by Futu AI
Biodexa Pharmaceuticals Plc, a company in the pharmaceutical sector, has filed a Registration Statement on Form F-1 with the United States Securities and Exchange Commission (SEC) on March 18, 2024. The SEC, through a letter addressed to Stephen Stamp, the Chief Executive Officer of Biodexa Pharmaceuticals, dated March 20, 2024, has informed the company that it has not reviewed and will not review the registration statement. The SEC's letter also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The letter further refers Biodexa Pharmaceuticals to Rules 460 and 461 should they wish to request acceleration of the process. Chris Edwards from the SEC's Division of Corporation Finance Office of Life Sciences has been designated as the contact person for any questions Biodexa Pharmaceuticals might have.
Biodexa Pharmaceuticals Plc, a company in the pharmaceutical sector, has filed a Registration Statement on Form F-1 with the United States Securities and Exchange Commission (SEC) on March 18, 2024. The SEC, through a letter addressed to Stephen Stamp, the Chief Executive Officer of Biodexa Pharmaceuticals, dated March 20, 2024, has informed the company that it has not reviewed and will not review the registration statement. The SEC's letter also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The letter further refers Biodexa Pharmaceuticals to Rules 460 and 461 should they wish to request acceleration of the process. Chris Edwards from the SEC's Division of Corporation Finance Office of Life Sciences has been designated as the contact person for any questions Biodexa Pharmaceuticals might have.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.